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INTRODUCTION
Bambuterol (BMB) is a bis-dimethylcarbamate prodrug of terbutaline (TBT) classified as a long-acting β 2-adrenoceptor agonists (LABA). BMB is given orally for the treatment of the symptoms of asthma, and other affections characterized by bronchospasm (Olsson et al., 1984 , Petrie et al., 1993 . In humans, the oral administration of BMB results in a slow production of TBT making a single daily dose of BMB sufficient to maintain therapeutic levels of TBT . BMB itself has no bronchodilating effect, but it is metabolized in vivo by plasma butyrylcholinesterase (BChE, EC 3.1.1.8) into bambuterol monocarbamate (MONO, inactive) which is further metabolized by the same enzyme into the pharmacologically active compound, TBT . The two-step hydrolysis is described by the second-order kinetic constants 1 I k and 2 I k ( Fig. 1 ). The hydrolysis mechanism in each step consists of a first stage in which one carbamate group of BMB or MONO is transferred to the active site of the enzyme which therefore results temporarily inhibited. In a successive stage the enzyme activity is restored by water that removes the carbamyl group from the active site with a rate constant k 3 (O'Brien et al., 1966; Main, 1979) . The inhibition of plasma BChE occurring during the hydrolysis of BMB into TBT is traditionally considered the main reason accounting for the slow production of TBT observed in vivo (Sitar, 1996) . An oxidative pathway for the biotransformation of BMB into TBT, most likely driven by cytochrome P450-dependent oxidases, has been observed in rat liver microsomes Lindberg et al., 1989) . Some evidence suggests that this metabolism might be significant also in humans (Bang et al., 1998) , although its real impact on the pharmacokinetics of BMB is still not clear and requires further investigation. (Fisher et al., 1988; Staun et al., 1990) , suxamethonium (Bang et al., 1990) and mivacurium (Ostergaard et al., 2000) observed in patients under BMB medication. BMB, which contains a chiral center, is currently synthesized and administered as a racemate, but there is some evidence that the (R)-enantiomer is more potent and less toxic than its mirror image (Morley, 2002; Tan and Cheng, 2009) . On this basis, (R)-BMB hydrochloride has been recently approved by the Chinese State Food and Drug Administration (SFDA) for phase I clinical trials and a preliminary pharmacokinetic study has been published (Zhou et al., 2014a) . On the light of the recent indications reported by the European Medicines Agency (EMA, 2012) , the Food and Drug Administration (U.S. FDA, 2012) , and successive suggestions (Yu and Tweedie, 2012) , metabolites that are present at 25% of the parent area under time-concentration curve (AUC) (EMA and FDA) or 100% of the parent AUC (Yu and Tweedie, 2012) should be subject of further in vitro characterization of the metabolite as a possible contributor to drug-drug interactions. This is clearly the case of BMB and MONO, since the AUC of MONO (in molar units) was found to be about 300% than the AUC of BMB in a recent pharmacokinetic study (Zhou et al., 2014b) . The renewed interest over BMB and the indications of the regulatory bodies emphasized the gaps in the current knowledge of BMB pharmacokinetics, and in particular on the interaction of its primary metabolite, MONO with BChE. BMB enantiomers have been characterized for their BChE inhibitory effects and (R)-BMB resulted to inhibit the enzyme about five-fold faster than (S)-BMB in vitro (Bosak et al., 2008) . The racemic mixture of MONO was found about 10-fold less potent as an inhibitor of human BChE than racemic BMB , but its hydrolysis kinetics has not been fully characterized. In addition, the inhibitory effect of MONO enantiomers on BChE has not yet been studied. 6 the BChE inhibition caused by BMB without the contribution of MONO and to evaluate the effect of the enzyme inhibition on the production rate of TBT. The contribution of TBT to the inhibition of BChE was not investigated since its role at therapeutic plasma concentrations can be considered insignificant (Kovarik and Simeon-Rudolf, 2004 ).
This article has not been copyedited and formatted. The final version may differ from this version. MONO) and its (S)-and (R)-enantiomers were synthesized by using racemic, (S)-and (R)-bambuterol as starting materials, respectively. Five aliquots of 10 mg of bambuterol hydrochloride (rac-S-or R-, 0.124 mmol) were solubilized in aqueous NaOH (0.25 M, 0.5 mL/aliquot) and left at room temperature (~26-28°C) for 12 h. The reaction was stopped by adding aqueous acetic acid (20% v/v, 100 μ L/aliquot). The fractions containing MONO (rac-S-or R-) were then isolated by solid-phase extraction (SPE).
Isolation of MONO by SPE.
A C-18 solid-phase extraction (SPE) cartridge (1g bed, Autoscience, Tianjin, PRC) was sequentially washed with 10 mL water, 10 mL of methanol and equilibrated with 10 mL NH 4 OH 0.2% in water (SOL 1). One aliquot of reaction mixture (600 μ L) was loaded onto the cartridge and terbutaline was eluted with 10 mL of SOL 1/methanol 90:10. MONO was eluted with 10 mL of SOL 1/methanol 60:40. The first mL of eluate was collected separately and discarded. Bambuterol (BMB) was eluted with 5 mL of Buffer ammonium acetate (50 mM, pH 4.6)/methanol 10:90. The cartridge was washed with 5 mL of water/methanol 10:90 and the procedure was repeated for the other aliquots of reaction mixture. The fractions of MONO obtained by SPE were pooled and the methanol content was reduced by a vacuum concentrator; aqueous HCl (0.05 M, 5 mL) was added and the fraction was lyophilized.
Chemical characterization. excess (e.e.) of the synthesized compounds are described in the supplemental data file (Supplemental methods S1 and S2).
.
In vitro measurements of BChE activity
The activity of BChE was measured in 96-well plates by an EnSpire Multimode 2300 plate reader (Perkin Elmer, MA) using the Ellman's spectrophotometric essay (Ellman et al., 1961) . (Zhou et al., 2014b) . This value represents a hypothetical minimum concentration of BMB reaching the circulation (i.e.
considering plasma protein binding, other metabolisms, distribution to tissues, and elimination of the three species negligible). Since the plasma protein binding of BMB is low [40-50% (Rosberg et al., 1993) ] and that of TBT is even lower [20% (Ryrfeldt and Ramsay, 1984) ], this factor is unlikely to modify significantly the hydrolysis kinetics of BMB. The physiologically relevant concentration of BChE was set at 6.42 U/mL. This value was chosen on the basis of the lowest activity found among the previously cited healthy volunteers (Zhou et al., 2014b ). Determination of the decarbamylation rate constant of N,N-dimethylcarbamyl-BChE, k 3 . The decarbamylation rate constant was determined by using a concentration of inhibitor able to almost completely inhibit the enzyme activity (Perola et al., 1997) . This solution was then diluted down to a concentration at which the inhibitor does not show any significant inhibition and the recovery of the activity was followed over time.
An aliquot of BChE stock solution (3 μ L) was mixed with a solution of rac-BMB 400 nM ( was performed at 30°C, because the hydrolysis of BMB at 37°C (in particular rac-BMB and (R)-BMB) was too fast to be monitored by a manual sampling; moreover 30°C resulted the highest temperature at which the evaporation of water did not influence significantly the measured concentrations within the whole duration of the experiment (3 hours).
UPLC/MS/MS analysis.
After the addition of the internal standard, the samples were centrifuged at 10,000 g at 4 °C for 10 min. The supernatant (2 μ L) was injected into the ultraperformance liquid chromatography tandem mass spectrometry (UPLC/MS/MS) system Waters Xevo-TQS (Waters, Manchester, UK). The chromatographic separation and the detection of BMB, MONO and TBT was performed by using a method validated for plasma samples (Zhou et al., 2014b) . The details of the analysis are reported as supplemental data (Supplemental method S3).
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where i v is the measured activity of the enzyme treated with the inhibitor after a given time of pre-incubation, 0 v is the activity of the enzyme treated with water at the same given time of pre-incubation, and t R , 0 R and ∞ R represent the residual fractional activity at time t , 0 and ∞ , respectively. The obs k values were then plotted versus the concentration of inhibitor ] [I . Since the relationship was linear for all the molecules under investigation, the data were analyzed as for a simple irreversible inhibition and the second-order inhibition (carbamylation) rate constant ( I k ) was calculated from eq. 3 (Marangoni, 2003; Gazić et al., 2006) :
The second-order carbamylation rate constants were defined as 1 I k when referring to the hydrolysis of BMB to MONO and 2 I k when referring to the hydrolysis of MONO to TBT.
The residual fractional activities obtained after 1 hour of incubation were plotted against the logarithm of inhibitor concentrations and the IC 50 values were obtained by fitting the data with a standard four-parameter logistic nonlinear regression analysis (Brooks et al., 2012) . Determination of the decarbamylation rate constants of N,N-dimethyl-BChE, k 3 . The decarbamylation rate constant (k 3 ) was calculated by plotting the natural logarithm of the measured inhibited fraction against time according to eq. 4 (Perola et al., 1997) :
where i v is the measured activity of the enzyme pre-incubated with the inhibitor at a given time (t) after dilution, 0 v is the activity of the enzyme pre-incubated with water at the same time after dilution. The slope of the linear data regression gives 3 k − .
Determination of k I values from UPLC-MS/MS data combined with enzymatic inhibition data obtained at the same physiologically relevant concentration of BChE and inhibitors.
The averaged time-course concentration profiles of BMB, MONO and TBT as measured by UPLC-MS/MS upon incubation of BMB and MONO with BChE were combined to the enzymatic inhibition data obtained in the same experimental conditions and analyzed by the WEB server ENZO [http://enzo.cmm.ki.si (Bevc et al., 2011) ] in order to obtain the secondorder carbamylation rate constants ( I k ).
The hydrolysis model used to analyze BMB enantiomers is reported in Figure 2A : BMB is hydrolyzed in a single step (i.e. the BMBenzyme complex is considered irreversible), yielding MONO and the inactive carbamylThis article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2B ).
In the case of racemic compounds (rac-BMB and rac-MONO), the above mentioned models, considering the racemate as a single compound) were used to obtain a numerical value of
in addition more complex models were evaluated, for which the two enantiomers (at half concentration of the respective racemate) act as different compounds and compete kinetically for the hydrolysis (Fig. 2C and 2D ). The concentration of BChE (necessary to obtain the I k values) was set at 80 nM as this value best fit both UPLC-MS/MS and enzymatic inhibition experimental data for all the compounds. The value of 3 k was fixed for all the computational analyses at the experimental value obtained at 30°C (0.006424 min -1 , Tab. 1). Residual sum of squares (RSS) values were used to evaluate the goodness of fit of the different models to the experimental MS data. The ordinary differential equations (ODEs) describing each model are reported as supplemental data (Supplemental method S4).
Calculation of the contribution of MONO to the inhibition of BChE displayed by BMB.
In order to estimate the contribution given by MONO to the enzyme inhibition observed for BMB, the I k values obtained at 30°C and 37°C were used to calculate the theoretical BChE inhibition profiles generated by the hydrolysis of BMB enantiomers without the contribution of the MONO metabolites, according to the model reported in 
RESULTS
Synthesis of rac-bambuterol monocarbamate hydrochloride and its single enantiomers
The products were obtained as a white powder (yield, 79% Both BMB enantiomers showed a time-and concentration-dependent inhibition of purified BChE (Supplemental Figure 1) . For both the enantiomers the relationship between concentration and k obs was linear (Fig.3B) , and the line passed through the origin indicating that the enzyme-inhibitor Michaelis complex is virtually irreversible (i.e. all the inhibitor that binds the enzyme is hydrolyzed) (Main, 1969) . rac-BMB and rac-MONO are in good agreement with previously reported data obtained with whole blood (2.7 nM and 50 nM for rac-BMB and rac-MONO, respectively) .
Determination of the decarbamylation rate constants, k 3
The inhibition of BChE by BMB and MONO enantiomers was completely reversible, as the enzyme was able to recover 95% of its activity in 4 hours at 37°C (Fig. 3C) . The recovery speed at 30°C was about half of that at 37°C (Fig. 3C , Tab. 1). The decarbamylation rate constant (k 3 ) measured at 37°C (Tab. 1) is in very good agreement with the value of 0.011 min -1 obtained with whole blood at the same temperature (value obtained replotting data published in Tunek and Svensson, 1988 according to eq. 4).
Enzyme inhibition a physiologically relevant concentration of BChE and inhibitors
The increase of concentration of BChE up to a physiologically relevant range (6.42 U/mL) did not modify the inhibition pattern observed for the different inhibitors at lower concentrations of enzyme. (R)-BMB was the fastest inhibitor, followed by (S)-BMB, (R)-MONO and (S)-MONO (Fig. 6A ). BMB and MONO racemates inhibited the enzyme with an intermediate kinetics within those of their respective single enantiomers (Fig. 6A, 6B ). Moreover, the inhibitory power followed the same pattern observed with lower enzyme concentrations: after This article has not been copyedited and formatted. The final version may differ from this version. 
50%, (S)-BMB, 43%, (R)-MONO, 38%, rac-MONO, 28% and (S)-MONO, 15%.
Bambuterol and bambuterol monocarbamate as substrates of BChE at physiologically relevant concentrations
The concentration profiles of BMB, MONO and TBT obtained upon incubation of BMB and MONO enantiomers with physiologic concentrations of BChE at 30 ºC are reported in Fig. 4 .
The profiles obtained for the racemic mixtures are shown in Fig. 5 .
(R)-BMB was hydrolyzed very fast when incubated with a physiological concentration of BChE. After 1 min of incubation, ∼70% of (R)-BMB was hydrolyzed to MONO and a small
amount of TBT was already present (6% of the initial (R)-BMB concentration). The highest concentration of MONO was reached after 4 min of incubation (85% of the initial (R)-BMB concentration). (R)-BMB was completely hydrolyzed within 8 min and the MONO produced
from its hydrolysis was almost completely hydrolyzed (96%) to TBT in 3 hours. Half of the initial concentration of (R)-BMB was transformed to TBT (t ½ TBT ) in about 45 min (Fig. 4) .
(S)-BMB showed a much slower reactivity compared to (R)-BMB. However, most of the drug (93%) was hydrolyzed within 30 min and the highest concentration of MONO (85% of the initial (S)-BMB concentration) was reached after 30 min. After 3 hours the hydrolysis was still incomplete and the concentration of TBT was only 57% of the initial (S)-BMB concentration (t ½ TBT ~ 160 min, Fig. 4 ).
Initially the hydrolysis of rac-BMB was initially only slightly slower than that of (R)-BMB.
About 50% of rac-BMB was already hydrolyzed to MONO within 1 min and traces of TBT 
Data fitting. In order to obtain reliable k I values the concentration profiles of BMB, MONO
and TBT obtained upon incubation of BMB and MONO with a physiologically relevant concentration of BChE at 30°C were analyzed together with the inhibition profiles of BChE obtained in the same experimental conditions (Fig. 6 ). In fact, since a quite large range of enzyme concentrations gave a reasonable fitting of the concentration profiles (as far as they were higher than the concentration of inhibitor), the exact concentration of enzyme was required to calculate reliable k I . The molar concentration of active enzyme in the purified preparation used for the experiments was not known. Anyway, only a very small range of enzyme concentrations, centered at about 80 nM, could fit both the concentration profiles and the inhibition profiles of all the tested compounds. This concentration of BChE is in good agreement with the value (79 nM) that was previously estimated in plasma (Myers, 1952) confirming that the concentration of enzyme used for the experiments was representative of physiological conditions. The second-order carbamylation rate constants ( (Fig. 5) .
Calculation of the contribution of MONO to the enzyme inhibition showed by BMB. The k I
and k 3 values measured at 30°C and 37°C were used to calculate the theoretical enzyme inhibition profiles of BMB with and without the contribution of MONO. The calculated inhibition profiles at 30°C and 37°C are depicted in figure 6C and 6D, respectively and the results are summarized in Table 2 . (Fig. 7B). (R)-BMB shows a similar behavior with a slightly faster kinetics and at 80 nM a temporary reduction of the initial production rate of TBT is already observable. At the highest concentration tested (120 nM) both rac-BMB and (R)-BMB show initially a low rate of production of TBT and after about 1 hour the rate increases to values similar to those calculated at lower concentrations (Fig. 7B) . The range of concentrations for which the initial rate of production of TBT is almost constant (40-80 nM) corresponds to an inhibition of the enzyme activity in the range of about 50-80%, while a lower and higher inhibition correspond to a positive or to a temporary negative dependence of the production rate of TBT versus the concentration of BMB, respectively (Fig. 7A ).
This article has not been copyedited and formatted. The final version may differ from this version. The interaction of BMB and MONO enantiomers with BChE was studied from two different perspectives. First, the compounds were characterized as inhibitors of the enzyme, to obtain an indirect picture of the hydrolytic process. Then the hydrolysis model was confirmed by studying BMB and MONO as substrates of the enzyme by measuring the concentrations of reagents and products over the time. The enantioselective time-and concentration-dependent inhibition mechanism obtained when BMB enantiomers were used as inhibitors is in agreement with previously reported findings and confirm the hydrolysis model (Fig. 1) previously proposed Simeon-Rudolf, 2004, Gazić et al., 2006) . In fact, according to this model the interaction between BMB and BChE results in a virtually irreversible complex formation and this is consistent with the linear correlation between the pseudo-first order rate constant ( obs k ) and BMB concentration (Fig. 2B ). In addition, the IC 50 , I k and k 3 values obtained for BMB within this work are in good agreement with those obtained with plasma and whole blood, confirming that the purified enzyme is a reliable model to study the hydrolysis of BMB catalyzed by BChE and that their interaction is not significantly affected by other blood constituents. In this study we demonstrated that the interaction between MONO enantiomers and the enzyme follows the same mechanism This article has not been copyedited and formatted. The final version may differ from this version. As a further confirmation of the hydrolysis model (Fig. 1) , when BMB and MONO enantiomers were studied as substrates of the enzyme, the experimental concentration profiles of substrates and products provided a very good fit with those computed according to the model (Fig. 4) . To emphasize this aspect, the experimental I k values were used to calculate the theoretical BChE inhibition profiles of BMB enantiomers without the contribution of the MONO generated during their hydrolysis ( Fig. 6C and 6D , Tab.2). As an example, the calculation of the contribution of (R)-BMB to the total enzyme inhibition revealed that the hydrolysis of (R)-MONO enhanced the inhibitory effect of (R)- 
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BMB by 25% and, at 37°C, it increased the recovery time of the enzyme of about 40% (Tab.
2). In addition, the contribution of MONO greatly enhances the effect of BMB chirality on BChE inhibition in terms of both maximum inhibition and duration of effect ( Fig. 6C and 6D, Tab.2). In other words without the contribution of the respective MONO enantiomers the maximum inhibition and the duration of inhibition of (R)-BMB and (S)-BMB are quite similar.
The analysis of the impact of BChE inhibition by rac-BMB and (R)-BMB over the initial production rate of TBT (Fig. 7) showed that the increase of production rate expected upon the increase of substrate concentration is almost perfectly balanced by the decrease of rate due to the reduction of active enzyme. This is especially noticeable in the range of BMB concentrations responsible for a maximum inhibition within 50% and 80%, which is the normal range of inhibition measured upon oral administration of rac-BMB in pharmacokinetic studies Sitar et al., 1992; Ahlström et al., 1999) . Thus the inhibition of the enzyme affects the initial production rate of TBT by keeping it constant over a relatively wide range of concentrations of administered BMB, rather than lowering it (Fig. 7) . However, the calculations showed that a dose of BMB able to inhibit the enzyme up to 95% can slow down the rate of production of TBT, even though only for a very short time (less than 90 min, Fig. 7 ). This effect can be reasonably ascribed mainly to a reduction of the hydrolysis rate of MONO, rather than a reduction of the hydrolysis rate of BMB. In fact, due to its lower k I value, the hydrolysis rate of MONO is much more sensitive to the concentration of active enzyme than BMB.
Taken together these data demonstrate that the inhibition of BChE by MONO accounts for a significant part of the inhibition observed for BMB in physiological conditions, particularly for the (R)-enantiomer. Furthermore the hydrolysis of MONO by BChE has a larger impact on the pharmacokinetics of BMB than previously considered;, therefore, the concentration The hydrolysis models employed for BMB and MONO enantiomers are depicted in Fig. 2A and 2B, respectively. The fitted curves obtained by ENZO are shown for visual comparison with the experimental data (light blue solid line). 
TABLES
